A Novel Oral Drug for the Treatment of Moderate to Severe Crohn's Disease Would Earn 40 Percent Patient Share in the U.S. and Europe

Thursday, April 15, 2010 Press Release
Email Print This Page Comment
Font : A-A+

Abbott/Eisai's Humira Will Remain Decision Resources' Proprietary Clinical Gold Standard Through 2018, According to a New Report from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook